Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026

Franco Stevanato, Chairman and Chief Executive Officer of Stevanato Group

“Third-quarter results were in line with our expectations, with 8% organic revenue growth and a 150-basis-point expansion in adjusted EBITDA margin. Solid growth in our Biopharmaceutical and Diagnostics Solutions Segment and continued demand in non-GLP-1 biologics, which grew over 30% in the third quarter, helped offset lower GLP-1 revenue and softer performance in the Engineering Segment. Looking to next year, we now anticipate lower volumes and revenue from GLP-1s than previously expected which we believe will temporarily moderate growth in 2027. We have already made meaningful progress in backfilling the expected lower revenue and we remain confident in our ability to grow low single digits next year, based on what we know today.”

Franco Stevanato, Chairman and Chief Executive Officer of Stevanato Group

“The demand environment for injectable biologics remains structurally strong, supported by scientific innovation, the expansion of biosimilars and the shift toward self-administered therapies. We continue to invest with discipline in high-value containment and delivery solutions, expand capacity across our global network, and advance differentiated platforms such as our groundbreaking Alba(®) syringes to our integrated device platforms such as our Alina(®) pen injector. These capabilities position Stevanato Group to support customers across the drug lifecycle and deliver sustainable, profitable long-term growth.”